Saved by Divine Intervention, Advocacy and Immunotherapy!
My brother was diagnosed with Stage IV "pancreatic cancer" in January, FOLFIRINOX failed, we advocated for immunotherapy (against the skepticism of multiple oncologists) and a recent CT scan showed exceptional response. Below is the timeline followed by the story of how divine intervention, advocacy and immunotherapy saved my brother.
Important note: This involves a rare subtype (sarcomatoid features, ~3% of pancreatic cancer cases). I'm not claiming immunotherapy works for all pancreatic cancer — but if you or a loved one fall into that 3%, this information could change your treatment path entirely.
Timeline at a glance:
- Late December 2025 — ER with abdominal pain. CT reveals 17+ cm cystic mass on the tail of the pancreas and liver lesions.
- Early January 2026 — Biopsy confirms poorly differentiated carcinoma with sarcomatoid features.
- Late January 2026 — Starts FOLFIRINOX (standard pancreatic cancer chemo). Severe side effects on both cycles.
- Early February 2026 — Comprehensive genomic profiling results come back: KRAS G12I, PD-L1 TPS 90%, CPS 92, MSI-stable, TMB-low and no BRCA mutations.
- February 26, 2026 — Restaging CT and PET scan show progression: liver lesions significantly increase, reference lesions growing. FOLFIRINOX has failed after ~4 weeks.
- March 11, 2026 — First dose of pembrolizumab (Keytruda) (oncologists skeptical)
- March 19, 2026 — ER visit for temperature spike. Multiple tests showed no infection — the fever may have been an immune activation response, which can occur when immunotherapy triggers a strong immune system response against the tumor. CT shows: liver lesions stable to slightly decreased. Early signal of response after only 1 treatment.
- May 20, 2026 — Restaging CT: "marked decrease" in liver lesions (one down 70%, another down 50%+), primary mass slightly smaller, no new disease anywhere. Confirmed deep partial response.
From diagnosis to confirmed immunotherapy response: ~5 months. From chemo failure to scan showing dramatic shrinkage: under 3 months on pembrolizumab.
Our Story
As noted above, my family's life was turned upside down when my brother was diagnosed with Stage IV "pancreatic cancer" in January and given only months to live. Having a background in data analysis and more recently AI use, I became the data scientist for the family. Both the local oncologist and Mayo Clinic commented that the size of the mass was highly unusual, something I confirmed in my research. I also found that my brother's genomic profiling was also rare, such as the high PD-L1 rate.
Through prayer and fasting (divine intervention) I stumbled upon medical journals that indicated sarcomatoid features in pancreatic cancer (often referred to as SCP) could indicate a positive reaction to immunotherapy even without MSI or BRCA. The local oncologist blew us off but after exchanging several messages with Mayo Clinic they finally gave me a letter of recommendation to add immunotherapy to FOLFIRINOX. However FOLFIRINOX was killing my brother and there was no evidence to suggest it would work with SCP so we got a 3rd opinion.
The 3rd oncologist was also skeptical of immunotherapy but recommended we get a scan to see if FOLFIRINOX was doing anything before making a decision. CT showed significant progression on chemo so the decision to drop FOLFIRINOX was easy, however the 3rd oncologist advocated for trying Gemcitabine + Abraxane and was skeptical of immunotherapy, blowing off my research.
During this time I was also looking into trials (with the help of PanCAN, these guys are amazing) and found a promising trial where they combine immunotherapy with a KRAS inhibitor ((TLN-372 + Pembrolizumab) NCT Number: NCT07204340) so we headed to our 4th oncologist.
Initially the 4th oncologist also insisted that immunotherapy does not work on pancreatic cancer but took a minute to hear me out and look at my research, finally endorsing immunotherapy and putting us on the trial list.
First dose of immunotherapy was administered locally on March 11, 2026 (by skeptical oncologist #1). 7 days later on March 18th my brother's temp spiked to dangerous levels and he had to go into the ER where they immediately assumed an infection, however multiple tests showed none and CT scan showed early signs that immunotherapy (after only 1 week) was working. In hindsight, the fever was likely an immune activation response — his immune system ramping up against the tumor — not an infection. It went from a terrifying night to one of the first real signs the treatment was doing something. Weekly labs indicated continued liver function improvement, also indicating immunotherapy was working.
Fast forward to May 20th (after 4 immunotherapy doses), Restaging CT: "marked decrease" in liver lesions (one down 70%, another down 50%+), primary mass slightly smaller, no new disease anywhere.
Additional Notes:
- I do not have a medical background but I utilized Claude Projects and Gemini Gems to help me analyze data, medical journals, labs, and conduct research. Ultimately my AI projects became a well-trained "oncologist" specializing in SCP (Sarcomatoid Carcinoma of the Pancreas). I spent hundreds of hours collecting data and fine-tuning my projects.
- Oncologists are not looking for sarcomatoid features or elevated PD-L1 rates in pancreatic cancer patients, however ~3% of patients likely have this and could be candidates for immunotherapy.
- I believe with all my heart that God intervened on multiple occasions to save my brother. It's a longer story but I want to advocate for faithful, diligent prayer and fasting.
- My brother did take Fenbendazole between chemo and immunotherapy as well as a couple doses during immunotherapy. To be clear, I don't give it any credit but I want to be fully transparent. Some people (like Joe Tippens) give Fenben a ton of credit but I believe the science points towards immunotherapy. Whether or not drugs like Fenben and Ivermectin can help enhance immunotherapy or not I believe is unclear.
Recommendations — What I'd Tell Someone in Our Shoes:
- Get comprehensive genomic profiling done immediately. Not just a basic mutation panel — get the full workup including PD-L1 testing, MSI status, tumor mutational burden, and ideally RNA sequencing. Companies like Tempus and Foundation Medicine offer these. Tyler's PD-L1 score of 90% was the single most important data point in his entire case, and it would not have been tested on a standard panel. If your oncologist hasn't ordered this, ask for it by name.
- If your tumor has unusual features, question the diagnosis. Tyler's tumor was initially labeled pancreatic cancer and treated with the standard playbook. But the sarcomatoid features, sky-high PD-L1, rare KRAS variant (G12I), completely normal tumor markers (CA 19-9, CEA, AFP) despite massive disease burden, and unusual cystic morphology all pointed away from typical pancreatic cancer. If things don't add up — the tumor is unusually large, markers are unexpectedly normal, or the pathology mentions unusual features — push for additional pathology review at an academic cancer center.
- Don't accept "immunotherapy doesn't work for your cancer type" without knowing YOUR tumor's specific biology. That statement is based on averages across a cancer type. Tyler's tumor is MSI-stable with low TMB — the two most common reasons immunotherapy gets approved — and he's still having a dramatic response. His response is being driven by PD-L1 expression and sarcomatoid biology, which is a completely different pathway. If your PD-L1 is high or your pathology shows sarcomatoid features, advocate for immunotherapy regardless of your cancer's general reputation.
- Get multiple opinions from academic cancer centers. Tyler's local oncologist would not have recommended pembrolizumab. It took input from Mayo Clinic and Washington University/Siteman Cancer Center to get the right treatment plan. If you're at a community oncology practice and your initial treatment isn't working, seek a second (or third, or fourth) opinion at a major cancer center. PanCAN (Pancreatic Cancer Action Network) was an incredible resource for us in navigating this — I highly recommend reaching out to them.
- If chemo fails quickly, that itself is information. Tyler's tumor blew through FOLFIRINOX in about 4 weeks — that's dramatically faster than the typical 6-month median progression-free survival. That primary chemoresistance, combined with the other unusual features, was actually a clue that this wasn't behaving like standard pancreatic cancer. A failed treatment isn't just a setback — it's data that should reshape the conversation about what to try next.
- Be an active participant in your care. Our family researched clinical trials, tracked lab values week to week, coordinated between multiple institutions, and prepared specific questions for every appointment. You don't need a medical degree to do this — you need to be willing to read, ask questions, and not back down when something doesn't feel right. AI tools like Claude and Gemini made it possible for me to engage with medical literature I never could have understood on my own.
- Track everything. I kept a running file of every lab result, every scan measurement, every doctor's note. When you can show an oncologist a trend line instead of just asking a question, the conversation changes. Data is your leverage.
- Pray. I believe prayer and fasting played a role in guiding our family to the right information at the right time.